Objective. Ulcerative colitis (UC) is a chronic idiopathic inflammatory bowel disease whose treatment strategies remain unsatisfactory. This study aims to investigate the mechanisms of Quyushengxin formula acting on UC based on network pharmacology. Methods. Ingredients of the main herbs in Quyushengxin formula were retrieved from the Traditional Chinese Medicine Systems Pharmacology (TCMSP) database. Absorption, distribution, metabolism, and excretion properties of all ingredients were evaluated for screening out candidate bioactive compounds in Quyushengxin formula. Weighted ensemble similarity algorithm was applied for predicting direct targets of bioactive ingredients. Functional enrichment analyses were performed for the targets. In addition, compound-target network, target-disease network, and target-pathway network were established via Cytoscape 3.6.0 software. Results. A total of 41 bioactive compounds in Quyushengxin formula were selected out from the TCMSP database. These bioactive compounds were predicted to target 94 potential proteins by weighted ensemble similarity algorithm. Functional analysis suggested these targets were closely related with inflammatory-and immune-related biological progresses. Furthermore, the results of compound-target network, target-disease network, and target-pathway network indicated that the therapeutic effects of Quyushengxin on UC may be achieved through the synergistic and additive effects. Conclusion. Quyushengxin may act on immune and inflammation-related targets to suppress UC progression in a synergistic and additive manner.
Introduction
Ulcerative colitis (UC) is a chronic and progressive immunologically mediated disease causing consecutive mucosal inflammation of the colon [1, 2] . The onset of UC is most often during young adulthood, which is well characterized by homogeneous and continuous lesions [3] . Although the incidence of UC is increasing in Asia, it is highly diagnosed in the developed countries, especially in Western Europe and North America. Previous reports showed that the overall incidence and prevalence of UC are nearly 1.2/20.3 cases and 7.6/245 per 100,000 persons per year, respectively [4, 5] .
UC therapy is aimed to reduce the recurrent rate, as well as improve the life quality and minimize drug-related adverse events. Basic therapies for UC are determined based on the severity of symptoms, which are often thought as step-up approaches. To date, 5-aminosalycilates (5-ASAs) have been the mainstay for treatment of mild-tomoderate UC [6] . Though 5-ASAs are safe and have no dose-related toxicity in short-term use with a dose-response efficacy, long-term use of them might induces adverse events, such as headache, diarrhea, nausea, interstitial nephritis, and hepatitis. In addition, patients with more moderate-to-severe UC after 5-ASAs therapy are typically treated with corticosteroids, and these patients are often followed by transition to a steroid-sparing agent with a thiopurine, adhesion molecule inhibitor, or anti-tumor necrosis factor (TNF) agent [6] . However, these corticosteroid-based therapies also accompany with side effects, such as cataracts, osteopenia, avascular necrosis, insomnia, mood changes, delirium, glaucoma, and adrenal insufficiency [7, 8] . Besides, despite improved medical therapies, it is estimated that about 15% of UC patients still require proctocolectomy [9] . Therefore, it is of great significance to develop more optimized and integrated therapies for UC patients.
To date, an increasing number of traditional Chinese herbal compounds are successfully used for treating UC with less side effects, such as Gegen Qinlian decoction [10] , Jianpi Qingchang decoction [11, 12] , Zhikang capsule [13] , Huangkui Lianchang decoction [14] , and Qingchang Wenzhong decoction [15, 16] . Quyushengxin formula is mainly composed of four herbs, Panax ginseng C.A. Mey. (Araliaceae), Astragalus membranaceus (Fisch) Bunge, Pulsatilla chinensis (Bge.) Regel, and Coptis chinensis Franch. Our clinical practice demonstrated Quyushengxin formula could relieve the clinical symptoms in active stage and suppress the inflammatory reaction of UC patients and could be used for treating mild-to-moderate UC [17] . Although the therapeutic effects of Quyushengxin on UC are attractive, molecular mechanisms of its action remain to be further elucidated.
Traditional Chinese medicine-(TCM-) oriented network pharmacology provides us a novel way to unveil the molecular mechanisms of TCM through pharmacokinetic evaluation, network/pathway analysis, and target prediction [18, 19] . In this study, we tried to unveil the molecular mechanisms of Quyushengxin formula acting on UC based on network pharmacology.
Materials and Methods

Screening of Potential Bioactive Compounds in Quyushengxin Formula. Traditional Chinese Medicine Systems
Pharmacology Database (TCMSP, http://lsp.nwu.edu.cn) is a systems pharmacology platform of Chinese herbal medicines that captures the relationships between drugs, targets, and diseases [20] . Ingredients along with their molecular weight (MW), water partition coefficient (AlogP), number of hydrogen bond donors (Hodn), number of hydrogen acceptors (Hacc), oral bioavailability (OB), Caco-2 permeability (Caco-2), blood-brain barrier (BBB), drug-likeness (DL), fractional negative accessible surface area (FASA) ,and half-life (HL), of all four herbs in Quyushengxin formula were retrieved from TCMSP. Then, absorption, distribution, metabolism, and excretion (ADME) properties, including OB, DL, and HL, were evaluated for screening out bioactive compounds. The potential bioactive compounds in Quyushengxin were predicted and sifted out via an integrated model including PreOB (for prediction of OL), PreDL (for prediction of DL), and PreHL (for prediction of HL) [21, 22] . In detail, OB value was obtained by OBioavail 1.1, and the compounds with OB ≥ 30% were selected out for further analysis [20, 23] . PreDL was utilized to calculate the DL index of compounds, and compounds with DL ≥ 0.18 were included for further research. The DL evaluation approach was constructed via both Tanimoto coefficient and molecular descriptors, and the formula is listed as follows:
where X was the molecular descriptors of herbal ingredients and Y showed the average molecular properties of all molecules in the DrugBank database (http://www.drugbank. ca/). Besides, PreHL was estimated by combining multivariable linear regression model and MLR (mixed logistic regression) algorithm [22] , as follows: Y t 1/2 � 13.310(± 13.31) + 13.376(± 13.37) × nArCO
where R 2 was the correlation coefficient of training set and Q 2 was the correlation coefficient of external test sets of the model. SEE was the estimated standard deviation of training set. F was the mean square ratio. Besides, N training indicated the number of chemical compounds in the training set, and N test indicated the number of chemical compounds in the test set. It was evidenced that there were eight descriptors satisfying the linear regression as follows: nArCO, H7m, D/ Dr09, N-070, C-032, JGI6, nRC�N, and Mor02e. Finally, 4 ≤ HL ≤ 8 was defined as appropriate selection criteria for drug HL evaluation.
Prediction of the Candidate Targets of Bioactive
Compounds. Weighted ensemble similarity (WES) algorithm was applied for predicting direct targets of the bioactive compounds via a large scale of drug target relationships [24] . Those targets with likelihood score ≥7 were deemed as direct targets in this study. Thereafter, candidate targets were mapped to Uniprot (http://www. uniprot.org/) for annotation and normalization. 
Functional Enrichment Analyses. Gene Ontology-(GO-)
biological processes (BPs) and Kyoto Encyclopedia of Genes and Genomes (KEGG, http://www.genome.jp/kegg/) pathways of the candidate targets of bioactive compounds were predicted via the Database for Annotation, Visualization, and Integrated Discovery (DAVID) database [25] with P < 0.05 as the criterion for significance.
Prediction of Target-Related Disease.
Target-related diseases were predicted by integrating multisource databases, including Comparative Toxicogenomics Database (CTD, http://ctdbase.org/) [26] , Therapeutic Target Database (TTD, http://bidd.nus.edu.sg/group/cjttd/) [27] , and PharmGKB database (https://www.pharmgkb.org/) [28] .
Network Construction.
Three kinds of networks in this study were established using Cytoscape 3.6.0 software [29] : compound-target network (C-T network), target-disease network (T-D network), and target-pathway network (T-P network). C-T network was composed of bioactive compounds and their potential targets, which was built to reveal the drug-target interactions. T-D network was built based on the potential targets and their related diseases. The pathway information of targets was selected from the results for KEGG pathway enrichment analysis by excluding those pathways with no relevance to UC based the latest pathological information of UC. T-P network was generated based on potential targets and UC-related pathways.
In the networks, the nodes represented compounds, targets, diseases, and pathways, and the edges displayed the interactions between two nodes. Furthermore, the significance of each node in the networks was assessed via one crucial topological parameter, namely, "degree," which was defined as the total of edges related with a node [30, 31] . Degree of all nodes was analyzed using plugin Networ-kAnalyzer of Cytoscape 3.6.0. 
Results
Screening of Potential Bioactive Compounds from Four
GO-BP Analysis.
To further validate whether biological processes enriched by candidate targets as mentioned above were correlated with UC, GO-BP enrichment analysis was performed via DAVID. The top 20 significant GO-BP terms are shown in Figure 2 . Most of them were strongly associated with inflammatory-and immune-related BPs such as "positive regulation of interleukin-6 biosynthetic process," "regulation of inflammatory response," "immune response," and "positive regulation of T-cell proliferation." In short, the 41 bioactive compounds in Quyushengxin formula may act on 94 candidate targets with inflammatory-and immunerelated effects to affect UC pathogenesis.
Establishment of T-D Network.
Target-related diseases were predicted by mapping them to integrating multisource databases, including CTD, TTD, and PharmGKB. A T-D network consisting of 90 targets and 4 kinds of diseases was built ( Figure 3 ). The four diseases were digestive system disease (degree � 60), pathology (degree � 49), cancer (degree � 23), and signs and symptoms (degree � 14).
T-P Network
Evaluation. KEGG pathway enrichment analysis was performed for the 94 targets, and T-P network was built. Results displayed that 79 targets could be further mapped to 78 pathways, including "mTOR signaling pathway," "T-cell receptor signaling pathway," "JAK-STAT signaling pathway," and "FOXO signaling pathway" (Figure 4) . The average degree of targets was 6.85, and the average degree of pathway was 2.8. In addition, 71 candidate targets could be mapped to several pathways (≥5), suggesting that these targets might mediate the cross-talk and interactions between different pathways. Besides, those pathways (70/78) mapped by multiple targets (≥8) might be the main factors for UC development and progression. These pathways were further divided into five function modules, including inflammatory regulation, immune regulation, 
Establishment of Compound-Target-Function Module
Network. By combing the networks above, a compoundtarget-function module network was built, which included 140 nodes (5 function modules, 41 compounds and 95 targets) and 653 edges ( Figure 5 ).
Details of 4 UC-Related Pathways from T-P Network
Analysis. To further unveil the multi-targets mechanisms of Quyushengxin formula in the treatment of UC, an integrated "UC-related pathway" was established according to the key pathways from the T-P network analysis. UCrelated pathways as shown in Figure 6 were composed of four pathways, including "T cell receptor signaling pathway" (hsa04660), "FOXO signaling pathway" (hsa04068), "JAK-STAT signaling pathway" (hsa04630) and "mTOR signaling pathway" (hsa04150). Those targets of the integrated "UC-related pathways" displayed the functional relationship with the UC-related proteins. UC-related pathways can be divided into three modules: immunology module, metabolism module and cell apoptosis-related module. Immunology module consisted of "T cell receptor signaling pathway" (hsa04660), and metabolism module consisted of "FOXO signaling pathway" (hsa04068). Cell apoptosis-related module was comprised of "JAK-STAT signaling pathway" (hsa04630) and "mTOR signaling pathway" (hsa04150). Taken together, Quyushengxin formula may well regulate immunology progress, metabolism progress and cell apoptosis progress to suppress UC progression. Evidence-Based Complementary and Alternative Medicine
Discussion
TCM has the advantages of high treatment efficacy and low treatment cost and side effect in the treatment of several diseases, including UC in China for several thousands of years [32] [33] [34] . After preliminary screening based on ADME properties, 41 potential bioactive compounds of Quyushengxin were screened out. Thereafter, 94 candidate targets of these 41 bioactive compounds were predicted for further analysis. Functional enrichment analyses suggested that these targets were closely related with inflammatory-and immune-related biological processes. Besides, a C-T network, a T-D network, a T-P network, and a compound-target-function module network were built. These networks indicated that the therapeutic effects of Quyushengxin on UC may be achieved through the synergistic and additive effects on multiple molecules and multiple pathways with immune and inflammatory effects to treat UC. Previous reports showed that the TCMSP-based method was reliable for screening out bioactive compounds of TCM for treatment of thrombosis [35] , gastric precancerous lesions [36] , cardiocerebrovascular disease [37] , and rheumatoid arthritis [38] . In this study, 41 bioactive compounds of Quyushengxin formula were selected out by using TCMSP database in combination with ADME properties. Most of the 41 compounds have been reported to have antiinflammatory and immune-regulatory effects. For example, quercetin (mol01, OB � 46.43%, DL � 0.28, HL � 14.40) could inhibit lipopolysaccharide-(LPS-) induced interleukin-(IL-) 6 production [39] , TNF-α production, and IL-8 production [40, 41] to exert anti-inflammatory effect. Besides, ursolic acid (mol17, OB � 16.77%, DL � 0.75, HL � 5.28) was reported to have human neutrophil elastase inhibitory effect both in vitro and in vivo [42] . Kaempferol (mol17, OB � 41.88%, DL � 0.24, HL � 14.74) was reported to significantly reduce the overproduction of TNF-α, IL-1β, IL-6, intercellular adhesion molecule-(ICAM-) 1, and vascular cell adhesion molecule-(VCAM-) 1 induced by LPS [43] . In addition, β-sitosterol (mol16, OB � 36.91%, DL � 0.75, HL � 5.36) and rutin (mol33, OB � 3.2%, DL � 0.68, HL � 6.22) were shared with significant anti-inflammatory activity [44, 45] . Above all, TCMSP-based systems pharmacology sifted out 41 potential bioactive compounds in Quyushengxin formula for treatment of UC.
Eight of the 94 targets have degree larger than 10 in the C-T network, including ESR1, PTGS2, NOS2, PTGS1, PPARG, NOS3, ESR2, and KCNH2. ESR1 was targeted by 34 compounds, which contributed to T-cell-mediated autoimmune inflammation by promoting T-cell activation and proliferation [46] . Besides, PTGS2 with the second highest degree played a critical role in the pathogenesis of gut inflammation [47, 48] . Moreover, PPARG was demonstrated to be able to downregulate proinflammatory cytokines production, such as IL-4, -5, and -6. In addition, PPARG could also enable to interfere with profibrotic molecules, such as platelet-derived growth factor (PDGF), IL-1, and transforming growth factor beta (TGF-β) [49] . These results suggested that Quyushengxin formula could probably treat UC by regulating anti-inflammatory action and the immune system. In this study, 94 targets were utilized to perform T-P network analysis, and the results showed that 79 targets could be further mapped to 78 pathways. Meanwhile, numerous pathways mapped by multiple targets might be the main factors for UC progression. Four pathways including "T-cell receptor signaling pathway," "FOXO signaling pathway," "JAK-STAT signaling pathway," and "mTOR signaling pathway" were closely associated with immune and inflammatory effects. T-cell receptors play significant role in function of T cells and formation of the immunological synapse, and they connected T cells and the antigen-presenting cells [50] . T-cell receptor pathway was reported to be important in regulation of UC [51, 52] . FOXO pathway plays a key role in regulating the expression of genes related to cell function such as apoptosis, cell cycle, oxidative stress, and differentiation [53] [54] [55] . FOXO3a was shown to control the inflammatory response and help maintain the homeostasis of the intestinal mucosa, which may also be a protective factor in the gut, and maintain a balance between the mucosal immune hemostasis against intravascular bacteria and inflammatory cytokines [56] . Besides, JAK-STAT pathway is the fulcrum for many important cellular processes, including cell survival, differentiation, proliferation, and regulation of immune function [57] . The mTOR pathway plays an important role in regulation of cell metabolism, proliferation, and autophagy. It is reported that mTOR signaling pathway was activated in bacteria-induced colitis in mice [58] . Inhibitors of mTOR signaling pathway are effective as anti-inflammatory drugs in treating colitis [59] [60] [61] . Therefore, Quyushengxin might suppress UC progression through targeting these anti-inflammation, autophagy, and immunoregulation pathways.
Nevertheless, limitations in this study could never be neglected. First, results in this study were mainly based on known chemical components in Quyushengxin, related targets, and pathways in UC. With the development of science and technology, new components in Quyushengxin, as well as new targets and pathways in UC will be further discovered, which will supply us with more theoretical evidences for further elucidation of underlying mechanisms of UC pathology. Second, the interaction relationships of the nodes in the networks, such as the action type, e.g., activation, inhibition, binding, and catalysis, and the action effect, e.g., positive, negative, and unspecified, are not investigated due to lack of these data. Third, due to the complex interaction between TCM and the human body, many of its acting mechanisms still needed to be further elucidated via pharmacokinetic test and other experiments.
Conclusion
In short, network pharmacology analysis of Quyushengxin showed that 41 bioactive components of Quyushengxin may act on 94 immune and inflammation-related targets to suppress UC progression in a synergistic and additive manner, which may provide us with a new starting point for a more detailed knowledge of mechanisms of UC pathogenesis.
